Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2
NCT00425035
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
115
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Renal Cell Carcinoma
Interventions
DRUG:
Panitumumab (ABX-EGF)
Sponsor
Amgen